Comparative Bioequivalence Study of 2 Fixed‐Dose Combinations of Vildagliptin and Metformin at a Tablet Strength of 50/1000 mg in Moroccan Volunteers
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1528 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Salma Lazrak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Bioequivalence Studies of the Sheikh Zaid Foundation, Rabat, Morocco. Hauptthemen laut MEDLINE: Metformin, Vildagliptin, Hypoglycemic Agents. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
This study evaluates the bioequivalence of 2 fixed‐dose combinations of vildagliptin (50 mg) and metformin (1000 mg) in healthy Moroccan volunteers. A single‐dose, randomized, simple‐blind, 2‐sequence, 2‐period crossover design was conducted with 30 participants, 28 of whom completed the study. The test product was compared to the reference product (by measuring pharmacokinetic parameters, including maximum plasma concentration, area under the concentration–time curve (AUC) from time zero to the last measurable time point, AUC from time zero extrapolated to infinity, and time to maximum concentration. Blood samples were collected at predefined intervals after dosing, and plasma concentrations of vildagliptin and metformin were determined using a validated liquid chromatography–tandem mass spectrometry method. Pharmacokinetic analysis showed comparable results between the 2 formulations. Both products met the bioequivalence criteria of 80%‐125% for maximum plasma concentration and AUC. Safety assessments revealed no serious adverse events, and both products were well tolerated. The study concluded that the test product is bioequivalent to the reference, supporting its therapeutic interchangeability in managing type 2 diabetes mellitus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Bioequivalence Studies of the Sheikh Zaid Foundation, Rabat, Morocco.
- Abulcasis International University of Health Sciences (UIASS), Rabat, Morocco.
- Cheikh Zaid International University Hospital, Rabat, Morocco.
Zitieren
APA
Lazrak, S., Ouaouda, O., Bektachi, J., Iraqi, M. A., El Khabbaz, C., & Cherrah, Y. (2025). Comparative Bioequivalence Study of 2 Fixed‐Dose Combinations of Vildagliptin and Metformin at a Tablet Strength of 50/1000 mg in Moroccan Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1528
Vancouver
Lazrak S, Ouaouda O, Bektachi J, Iraqi MA, El Khabbaz C, Cherrah Y. Comparative Bioequivalence Study of 2 Fixed‐Dose Combinations of Vildagliptin and Metformin at a Tablet Strength of 50/1000 mg in Moroccan Volunteers. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1528
BibTeX
@article{Lazrak2025,
author = {Lazrak, Salma and Ouaouda, Oumaima and Bektachi, Jalal and Iraqi, Mohamed Ali and El Khabbaz, Choukri and Cherrah, Yahya},
title = {Comparative Bioequivalence Study of 2 Fixed‐Dose Combinations of Vildagliptin and Metformin at a Tablet Strength of 50/1000 mg in Moroccan Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1528}
}
EUVIMED